The oral GLP-1 race got another contender at the American Diabetes Association's 2026 Scientific Sessions in June: Structure Therapeutics presented Phase 2 data on aleniglipron, a once-daily pill that drove roughly 16% weight loss with no plateau. Analysts called it "best-in-class" oral data — but it is still years from a pharmacy shelf, which raises the only question that matters for most readers: what can you actually get today?
Research-context information only. This article reports trial data and what it means for buyers. It is not medical advice. Talk to a licensed physician before starting any GLP-1 protocol.
The short version: aleniglipron is promising and entirely unavailable. The two oral and injectable routes that exist right now are FDA-approved orforglipron and compounded GLP-1 peptides — and that gap is exactly what most "new pill" searches miss.
What Structure Showed at ADA 2026
Aleniglipron — formerly known by its development code GSBR-1290 — is a once-daily oral small-molecule GLP-1 receptor agonist. That "small molecule" distinction matters: unlike injectable peptides such as semaglutide or tirzepatide, it survives the gut and works as a pill with no food or water timing restrictions, the same convenience profile as orforglipron.
In the Phase 2 ACCESS II trial, participants escalated from 5 mg daily up to 120 mg over 20 weeks, then were randomized at week 28 to hold 120 mg or push to 180 or 240 mg. The headline numbers over 44 weeks:
| Dose | Placebo-adjusted weight loss (44 wks) | Plateau? |
|---|---|---|
| 180 mg daily | ~15.3% | None observed |
| 240 mg daily | ~16.0-16.3% | None observed |
| Placebo | +1.1% (slight gain) | — |
Two things stood out to analysts. First, the curve had not flattened by week 44 — weight was still trending down, suggesting the ceiling is higher than the trial captured. Second, tolerability improved sharply versus earlier studies: among participants who reached 120 mg or higher, the adverse-event discontinuation rate was about 10%, with the usual GLP-1 GI complaints (nausea, mild diarrhea) as the dominant side effects.
Structure plans to meet with the FDA in the second quarter of 2026 on pivotal trial design and launch Phase 3 in the second half of 2026. That timeline puts realistic FDA approval no earlier than 2028.
What This Means for You
Here is the part the press releases bury: there is no way to buy aleniglipron. It is mid-pipeline, Phase 3 hasn't even started, and unlike semaglutide or tirzepatide there is no grey-market research version in circulation — it's a proprietary small molecule, not a peptide that compounding pharmacies or research vendors can synthesize. Anyone selling "aleniglipron" today is selling something else.
So if the ADA headlines sent you looking for an oral GLP-1, you have exactly two legitimate routes right now:
Route 1: The oral pill that already exists — orforglipron
Orforglipron (Foundayo) was FDA-approved in April 2026 — the first oral GLP-1 with no food or water restrictions, the same class aleniglipron is chasing. It delivered roughly 12-13% weight loss in Phase 3 and runs about $149/month self-pay, with commercial-insurance copays as low as $25 and Medicare Part D access starting July 1, 2026. It's a prescription drug, available through retail pharmacies and telehealth today. If a daily pill is the goal, orforglipron is the only approved one on the market.
Route 2: Compounded injectable GLP-1 peptides
If you want the strongest weight-loss data available and don't mind a weekly injection, compounded GLP-1 peptides remain the access route most of our readers use. The landscape hasn't changed this week — vetted vendors with current COA documentation still carry the three workhorses:
- Best Semaglutide Vendors — current pricing on 5mg and 10mg vials
- Best Tirzepatide Vendors — pricing on 10mg, 30mg, and 60mg vials
- Best Retatrutide Vendors — the triple agonist with the highest Phase 3 weight-loss numbers to date
- All Active Vendor Coupons — current discount codes across recommended vendors
The honest framing: aleniglipron may eventually be a cleaner option than today's compounded route — a pill, no needles, no reconstitution. But "eventually" is years out. The decision in front of you now is orforglipron versus an injectable peptide, not aleniglipron versus anything.
